Frederick National Lab and Q2 Solutions have been validating the kit as early users and plan to implement it in their clinical trial services.
The company said it will use the net proceeds for general corporate purposes and to fund ongoing operations and expansion of its business.
Although the study was small, the investigators believe it provides proof of principle for the usefulness of cell-free DNA to prognose and monitor glioblastomas.
The company will use its InVisionFirst-Lung test to study resistance mutations in patients treated with Pfizer's ALK inhibitor lorlatinib.
The validation of its current CLIA testing comes as Biocept is in the early stages of expanding to provide kit versions of its liquid biopsy tests.
Circulating tumor DNA detection in stage III colon cancer patients after surgery and adjuvant chemotherapy coincided with a rise in recurrence risk.
The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.
The Irvine, California-based firm said its "Revolution" system offer recovery rates of 70 to 90 percent across a wide range of liquid sample volumes.
The companies will use Foundation Medicine's FoundationOne CDx test as the baseline to define a set of unique variants that the codeveloped assays will monitor.
The company said it has seen progress in efforts to get FDA approval for its tissue and liquid biopsy tests as data continues to accumulate for pan-cancer utility.
Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.
An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.
Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.
In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.